CHINA Law and Practice Contributed by: Alan Zhou, Charlene Huang, Jenny Chen and Stephanie Wang, Global Law Office
Global Law Office was one of the first law firms in the People’s Republic of China (PRC) to have more than 600 lawyers practising in its Beijing, Shanghai, Shenzhen and Chengdu offices. Its life sciences and healthcare (L&H) group, also known as China Life Sciences and Healthcare Law (CLHL), is one of the leading practice groups in China. It provides “one-stop” legal services for every sector in the L&H industry, including R&D, clinical research organisations, pharmaceuticals, biotechnology, medical de- vices, supply producers and distributors, hos- pitals and other healthcare providers as well
as investment funds. The firm regularly advises clients on challenging L&H legal issues such as regulatory compliance, structuring transac- tions and contractual arrangements, realisation of pipeline and geographic expansions, capital raising and project financing, M&A, reorganisa- tions as well as IP protection, licensing and dis- tribution arrangements, settlement of disputes involving adverse effects in clinical trials and medical treatment. The firm has close links to industrial associations and makes recommen- dations on industry codes of conduct and com- pliance management standards.
Authors
Alan Zhou is the leading partner in the life sciences and healthcare practice group at Global Law Office. He has a strong background in the area, routinely representing
Charlene Huang is a partner and is based in Global Law Office’s Shanghai office. She has in-depth experience in M&A and cross-border licence deals, especially in the healthcare and
multinational corporations, well-known Chinese state-owned and private enterprises and private equity/venture capital funds. As a participant or an external counsel, he has been engaged by local authorities and industrial associations to advise on legislation and industrial standards in the life sciences and healthcare industry, including guidelines on compliance and risk control, e-healthcare, medical insurance reform and medical representative administration. His insights have been widely published at home and abroad.
life sciences sector. She has led projects involving outbound and inbound investment, acquisition of state-owned and private equity/ assets, pipeline consolidation or restructuring of multinational corporations and various licence or collaboration deals in the pharmaceutical, medical device and medical services sectors. She regularly provides support and advice on projects concerning cell therapy, gene therapy, digital healthcare, medical AI, etc. She also has in-depth experience in advising multinational companies in general corporate, cybersecurity and data management matters.
22
CHAMBERS.COM
Powered by FlippingBook